DSIP vs VIP
Both DSIP and VIP are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | DSIP | VIP |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 38 | 24 |
| Categories | sleep, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.